The peptide gained clinical interest because of a consistent pattern observed in rodent studies: BPC-157 accelerated healing of experimentally induced gastric ulcers, esophageal lesions, and intestinal anastomoses
Arterial and venous events negatively affect the prognosis of systemic and monogenic vasculitis, and represent a diagnostic challenge in clinical practice
Its structural stability and controlled degradation profile make it suitable for complex experimental designs
TB-500 refers to the complete 43-amino-acid sequence of Thymosin Beta-4 used in research literature
Methods Study Setting Launched in April 2015 in collaboration with the National Psoriasis Foundation, the CorEvitas Psoriasis Registry (ClinicalTrials.gov: NCT02707341) is an independent, prospective, multicenter, non-interventional study that enrolls adults ( 18 years of age) who have been diagnosed with psoriasis, are willing and able to provide written informed consent for participation, and started on or switched to an eligible psoriasis treatment (US Food and Drug Administration [FDA]-approved biologic and non-biologic systemic therapies) at enrollment or 12 months before enrollment [12]
